Prostate Carcinoma Surveillance Counterpoint: USA
Author:
Smith Angela,Pruthi Raj
Reference46 articles.
1. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol. 2001;165:1146–51.
2. Han M, Partin AW, Zahurak M. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169:517–23.
3. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Prostate Cancer.
http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf
. Accessed 12 Feb 2009
4. Pound CR, Partin AW, Epstein JI. Prostate-specific antigen after anatomic radical retropubic prostatectomy—patterns of recurrence and cancer control. Urol Clin North Am. 1997;24:395–8.
5. D’Amico AV. How to compare results after surgery or radiation for localized prostate carcinoma—prostate specific antigen (PSA) outcome (no), posttreatment PSA doubling time (maybe), or survival (yes)? Cancer. 2002;95:2041–3.